Actio Biosciences, Inc.’s Post

Check out our new case study!

Making cell and gene therapies safely on a commercial scale is a challenge we must overcome to make these innovative treatments available to more people at a reasonable cost. CDMOs, or Commercial Drug Manufacturing Organizations, are an important part of the modern pharmaceutical supply chain for small molecules, biologics, and now CGTs. The Center for Breakthrough Medicines is one of the newest CGT CDMOs. Learn more about them in this interview from the Bullpen!

I recently had the honor of addressing an esteemed audience, shedding light on the exceptional position of multinational pharmaceutical companies in Israel. Here's a succinct overview: The Multinational Influence: Drawing from Shimon Peres' words, "The world has become uncontrollable. Security has shifted from clashes between armies to acts of terror, and no country can control it. Into this void entered multinational corporations. These global companies have unparalleled achievements. A global company cannot be racist. A global company empowers people because it is built on the will of the individual. Such companies exert control without force. Without an army and a police force. “ 📊 Highlighting Israeli Strengths: Delivering Results with Big Numbers: When examining our clinical trials per capita, the density of our startups, our position as the third-highest country with NASDAQ-listed companies globally—only surpassed by the US and China—and Israel's ranking as the 28th largest economy worldwide, it's evident that we are making significant strides in terms of scale and impact. Focus on What Matters Most: Israel consistently prioritizes what's truly important—our nation. Nearly every Israeli has played a role, whether in defending our homeland, aiding those affected physically, emotionally, or financially, or ensuring business continuity, a cornerstone of our economy's success and our nation's enduring resilience. Pioneering: During wartime, our pioneering spirit shines through. The evolution in trauma medicine from the war's onset to the present showcases groundbreaking advancements. The innovations emerging from this period will offer invaluable insights for the global community. 🌟 Resilience in the Pharma Sector: Delivering with Big Numbers: With the highest number of clinical trials per capita in the world, we contribute over NIS 500 Million annually to our national system. Even during the war, our collaboration with the Ministry of Health (MOH) ensured our companies maintained clinical operations within Israel. Our resilient teams ensured that no patient was left behind.  Focusing on What Matters: From the onset of the war, guided by our commitment to improving lives, every multinational Pharma Israel company has worked consistently to maintain supplies, ensuring continued care for our patients. These actions represent just a glimpse of our proactive endeavors. Collectively, through our joint efforts, we've contributed over 26 million NIS. Pioneering Together: Our joint efforts have led us to embrace innovative initiatives. We've pivoted our strategies in novel ways, guaranteeing that patients continue to receive the best care, even in the face of wartime challenges. 🤝 Closing Thoughts: As we chart our path forward, let's continue to harness our strengths in delivering results with big numbers, pioneering first, and focusing on what matters most, ensuring a brighter, healthier future for Israel and its people.#nomatterwhat

This is optimal.

Exciting News !!! I am thrilled to share that NostraBiome has successfully been backed by one of the most forward thinking medtech funds- with the trust and commitment of Joseph Mocanu, Erki Mölder, Sigvards Krongorns and the entire team at Verge HealthTech Fund . Our mission to revolutionize the treatment of Inflammatory Bowel Disease ( IBD) and other immune-mediated conditions through advanced microbiome intelligence technology is now set to fly. As we embark on this transformative journey, I am also proud to announce that joining me at Nostra:Biome are some of the top executives I've had the pleasure of working with over the years. Their expertise will undoubtedly propel us forward as we strive to develop real solutions for real problems and help people who suffer. Valerio Lo Giudice who was my right arm and friend for over 9 years and helped me build the impossible in all my previous tech companies and ventures is the CTO and co-founder, setting now new standards and highs of the Microbiome and AI. Radu - Dumitru Dragomir a friend and colleague for over 12 years is our top Chief Medical Officer and co-founder, in charge of backing all our clinical operations. Valentin Moinescu a Pharma veteran and top medical entrepreneur helps NostraBiome to navigate the compicated medical world as Chief Sales Officer and co-founder. Stay tuned for more updates—there's plenty more to come as we work to improve the lives of millions suffering from IBD, Crohn's, IBS, and other immune diseases. Together, we're making history! #HealthTech #StartupFunding #Microbiome #PrecisionMedicine #InnovativeHealthcare #NostraBiome

🌟 Appreciation Post Alert! 🌟 Feeling grateful for my incredible circle of friends who are making significant impacts across various sectors. Today, I'm thrilled to highlight Emmanuel Akpakwu, the dynamic CEO of Axmed. 🎉 Why celebrate Emmanuel? His venture, Axmed, just secured a remarkable $2 million funding round, building on a $5 million grant from the Bill & Melinda Gates Foundation. 🔍 What challenge does Axmed tackle? Despite representing over 80% of the global population and bearing more than 90% of the world's disease burden, low- and middle-income countries see account for a mere 6% of global pharmaceutical revenues. This disparity stems from structural and commercial biases favouring rich economies. 🌍 How does Axmed plan to solve this? By offering a platform where governments and organisations from emerging nations can consolidate their drug orders. This aggregation creates large-scale demand, enticing manufacturers to supply essential medications at prices these countries can afford. Here's to Emmanuel and Axmed, bridging gaps and fostering health equity! 🌐✨ Below is an article from Forbes summarising Emmanuel and Axmed's milestone. https://lnkd.in/eA9JNVTq

The Basel #Healthtech Conference is off to a great start, with timely discussions on healthcare innovation and interesting perspectives on both early and late-stage investments. We’re looking forward to connecting with and hearing more from industry leaders, investors, startup founders, and other key decision makers on what to expect in 2024 and beyond.    Be sure to say hello to our CFO Tzahi Sarousi who will be back tomorrow for day two of the conference!   #BaselHealthtech2024 #clinicaltrials #clinicalresearch #drugdevelopment #biometrics #CRO #datamanagement

I look forward to sitting tomorrow fireside with Ed Tucker MD MBA at #CMO360 to chat about life sciences M&A, licensing and financing dynamics across the capital structure and royalties. Among other topics, we will explore what strategics are seeking with respect to collaboration partners (licensors). #M&A #Licensing #Biopharma

🌱 Embracing Renewal and Growth this Nowruz 🌱 As the first day of spring heralds the start of Persian New Year - Nowruz, it's a time to reflect on new beginnings and the promise of rejuvenation. At ThinkrBelle, Sigrun Watson and I embody the spirit of Nowruz year-round, nurturing fresh perspectives at the intersection of Pharma and Tech. In the same way that Nowruz represents a rebirth of nature, we at ThinkRBelle are dedicated to revitalizing healthcare. We stand as a bridge between the biopharmaceutical industry and the forward-thinking world of technology, sowing the seeds of innovation to bloom into solutions that enhance patient care and wellbeing. Our commitment mirrors the essence of Nowruz—celebrating life and the health of our communities. We cultivate a landscape where the fusion of pharma knowledge and tech ingenuity grows into a flourishing garden of therapeutic possibilities. As we welcome spring with open hearts, let's also open our minds to the transformative changes we can achieve together. Wishing everyone a Nowruz that's as inspiring and hopeful as the future we're building at ThinkRBelle. May this new season bring growth, health, and prosperity to all. #ThinkRBelle #HealthTech #PharmaTech #Innovation

👏🏽 Clinical evidence and a clear #regulatory plan as main drivers to #investment - Inaki Berenguer, from LifeX Ventures 👏🏽 Emphasis on the importance of piloting at hospitals before launching a #medtech solution - Ryan Collins, from MassMutual Ventures Great talk about investment drivers, very nicely moderated by - Helena Torras -, from Hans(wo)men Group, today at 4YFN! We’ll take this into account as we raise a 2m round to get The Blue Box Biomedical Solutions through clinical trials, regulatory and launch into the market.